Stephan Siebel1, Alfonso Galderisi1,2, Neha S Patel1,3, Lori R Carria1, William V Tamborlane1, Jennifer L Sherr1. 1. 1 Pediatric Endocrinology, Yale School of Medicine, New Haven, Connecticut. 2. 2 Department of Women and Children's Health, University of Padova, Padova, Italy. 3. 3 Department of Pediatric Endocrinology and Diabetes, Penn State Health, Hershey, Pennsylvania.
Abstract
OBJECTIVE: We have shown that "euglycemic DKA" in patients with type 1 diabetes receiving a sodium-glucose cotransporter 2-inhibitor (SGLT2i) is due to normal increases in rates of ketogenesis but blunted increases in plasma glucose levels. In this analysis, we assessed whether rescue treatment of early ketoacidosis with insulin is altered by SGLT2i use. RESEARCH DESIGN AND METHODS: Participants received 0.2 U/kg of aspart insulin after two 6-h interruptions of basal insulin that increased beta-hydroxybutyrate (BHB) by 1.2 ± 0.7 mmol/L before and by 1.5 ± 0.2 mmol/L during canagliflozin treatment. BHB and free fatty acid (FFA) were monitored every 30 min for 120 min after receiving a 0.2 U/kg subcutaneous injection of aspart insulin. RESULTS: Ten adults (23 ± 5 years) were studied. During the 120 min after rescue therapy with insulin, the reductions in BHB and FFA were nearly identical between the pre- and during canagliflozin treatment studies, respectively (-1.27 ± 0.76 and -1.13 ± 0.69, P = 0.671 for BHB and -0.50 ± 0.35 vs. -0.41 ± 0.41, P = 0.603 for FFA). CONCLUSION: These data indicate that turning ketogenesis off, as well as on, does not appear to be affected by SGLT2i use.
OBJECTIVE: We have shown that "euglycemic DKA" in patients with type 1 diabetes receiving a sodium-glucose cotransporter 2-inhibitor (SGLT2i) is due to normal increases in rates of ketogenesis but blunted increases in plasma glucose levels. In this analysis, we assessed whether rescue treatment of early ketoacidosis with insulin is altered by SGLT2i use. RESEARCH DESIGN AND METHODS: Participants received 0.2 U/kg of aspart insulin after two 6-h interruptions of basal insulin that increased beta-hydroxybutyrate (BHB) by 1.2 ± 0.7 mmol/L before and by 1.5 ± 0.2 mmol/L during canagliflozin treatment. BHB and free fatty acid (FFA) were monitored every 30 min for 120 min after receiving a 0.2 U/kg subcutaneous injection of aspart insulin. RESULTS: Ten adults (23 ± 5 years) were studied. During the 120 min after rescue therapy with insulin, the reductions in BHB and FFA were nearly identical between the pre- and during canagliflozin treatment studies, respectively (-1.27 ± 0.76 and -1.13 ± 0.69, P = 0.671 for BHB and -0.50 ± 0.35 vs. -0.41 ± 0.41, P = 0.603 for FFA). CONCLUSION: These data indicate that turning ketogenesis off, as well as on, does not appear to be affected by SGLT2i use.
Entities:
Keywords:
Insulin pump.; Ketogenesis; SGLT2i; Type 1 diabetes
Authors: Silvio E Inzucchi; Bernard Zinman; David Fitchett; Christoph Wanner; Ele Ferrannini; Martin Schumacher; Claudia Schmoor; Kristin Ohneberg; Odd Erik Johansen; Jyothis T George; Stefan Hantel; Erich Bluhmki; John M Lachin Journal: Diabetes Care Date: 2017-12-04 Impact factor: 19.112
Authors: Helena W Rodbard; Anne L Peters; April Slee; Anjun Cao; Shana B Traina; Maria Alba Journal: Diabetes Care Date: 2016-11-29 Impact factor: 19.112
Authors: Chantal Mathieu; Paresh Dandona; Pieter Gillard; Peter Senior; Christoph Hasslacher; Eiichi Araki; Marcus Lind; Stephen C Bain; Serge Jabbour; Niki Arya; Lars Hansen; Fredrik Thorén; Anna Maria Langkilde Journal: Diabetes Care Date: 2018-07-19 Impact factor: 19.112
Authors: Neha S Patel; Michelle A Van Name; Eda Cengiz; Lori R Carria; Stuart A Weinzimer; William V Tamborlane; Jennifer L Sherr Journal: Diabetes Technol Ther Date: 2017-10-25 Impact factor: 6.118
Authors: Paresh Dandona; Chantal Mathieu; Moshe Phillip; Lars Hansen; Diethelm Tschöpe; Fredrik Thorén; John Xu; Anna Maria Langkilde Journal: Diabetes Care Date: 2018-10-23 Impact factor: 19.112
Authors: Satish K Garg; Robert R Henry; Phillip Banks; John B Buse; Melanie J Davies; Gregory R Fulcher; Paolo Pozzilli; Diane Gesty-Palmer; Pablo Lapuerta; Rafael Simó; Thomas Danne; Darren K McGuire; Jake A Kushner; Anne Peters; Paul Strumph Journal: N Engl J Med Date: 2017-09-13 Impact factor: 91.245
Authors: Anne L Peters; Elizabeth O Buschur; John B Buse; Pejman Cohan; Jamie C Diner; Irl B Hirsch Journal: Diabetes Care Date: 2015-06-15 Impact factor: 19.112